Targeting angiogenesis in head and neck cancer

Current Cancer Drug Targets

Volumn 7, Issue 7, 2007, Pages 643-649

  Saba, Nabil F ^a,b   Shin, Dong M ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY   (United States)

^b Glenn Bldg ^*  (United States)

Author keywords

Angiogenesis; Antiangiogenesis; Endothelial; Endothelial growth factor; Head and neck; Squamous cell carcinoma; Targeted therapy; VEGF

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA2 INTERFERON; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 6; INTERLEUKIN 8; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; RAS PROTEIN; REBIMASTAT; SCATTER FACTOR; SORAFENIB; SUNITINIB; TOPOTECAN; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ANGIOGENESIS; COLON CANCER; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; RASH; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 35948998510     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907782418356     Document Type: Review

References (87)

1. Folkman, J. Clinical applications of research on angiogenesis. N. Engl. J. Med. 1995, 333, 1757-1763.
2. Kerbel, R.; Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2, 727-739.
3. Rizvi, N. A.; Humphrey, J. S.; Ness, E. A.; Johnson, M. D.; Gupta, E.; Williams, K.; Daly, D. J.; Sonnichsen, D.; Conway, D.; Marshall, J.; Hurwitz, H. A phase I study of oral BMS-275291, a novel nonhydroxamate sheldase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin. Cancer Res. 2004, 10, 1963-1970.
4. Cohen, E. E. W. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin. Oncol. 2004, 31, 755-768.
5. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R. C.; Ghafoor, A.; Feuer, E. J.; Thun, M. J. Cancer Statistics, 2005. CA Cancer J. Clin. 2005, 55, 10-30.
6. Greenlee, R. T.; Murray, T.; Bolden, S.; Wingo, P. A. Cancer Statistics, 2000. CA Cancer J. Clin. 2000, 50, 7-33.
7. Sridhar, S. S.; Shepherd, F. A. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003, 42(Suppl. 1), S81-S91.
8. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
9. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6, 389-395.
10. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy. A new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989.
11. Bergers, G.; Song, S.; Meyer-Morse, N.; Bergsland, E.; Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111, 1287-1295.
12. Seghezzi, G.; Patel, S.; Ren, C. J.; Gualandris, A.; Pintucci, G.; Robbins, E. S.; Shapiro, R. L.; Galloway, A. C.; Rifkin, D. B.; Mignatti, P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell. Biol. 1998, 141, 1659-1673.
13. Laird, A. D.; Vajcoczy, P.; Shawver, L. K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S. R.; Blake, R. A.; Fong, T. A.; Strawn, L. M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K. P.; McMahon, G.; Cherrington. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000, 60, 4152-4160.
14. Scott, P. A.; Harril, A. L. Current approaches to targeting cancer using antiangiogenesis therapy. Cancer Treat. Rev. 1994, 20, 393-412.
15. Hobson, B.; Denekamp, J. Endothelial proliferation in tumors and normal tissues: continuous labelling studies. Br. J. Cancer 1984, 49, 405-413.
16. Moeller, B. J.; Dreher, M. R.; Rabbani, Z. N.; Schroeder, T.; Cao, Y.; Li, C. Y.; Dewhirst, M. W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005, 8, 99-110.
17. Ferrara, N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 1995, 36, 127-137.
18. Houck, K. A.; Ferrara, N.; Winer, J.; Cachianes, G.; Li, B.; Leung, D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 1991, 12, 1806-1814.
19. Keck, P. J.; Hauser, S. D.; Krivi, G.; Sanzo, K.; Warren, T.; Feder, J.; Connolly, D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246, 1309-1312.
20. Zhang, L.; Chen, Q. R.; Mixson, A. J. Antiangiogenic gene therapy in cancer. Curr. Genomics 2000, 1, 117-133.
21. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
22. Riedel, F.; Gotte, K.; Hormann, K.; Grandis, J. R. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy. Adv. Otorhinolaryngol. 2005, 62, 103-120.
23. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362, 841-844.
24. Saleh, M.; Stacker, S. A.; Wilks, A. F. Inhibition of growth of C6 glioma cells in vivo by expression of anti-sense vascular endothelial growth factor sequence. Cancer Res. 1996, 59, 895-900.
25. Ke, L. D.; Fueyo, J.; Chen, X.; Steck, P. A.; Shi, Y. X.; Im, S. A.; Yung, W. K. A novel approach to glioma gene therapy: downregulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int. J. Oncol. 1998, 12, 1391-1396.
26. Takahashi, Y.; Tucker, S. L.; Kitadai, Y.; Koura, A. N.; Bucana, C. D.; Cleary, K. R.; Ellis, L. M. Vessel count and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. 1997, 132, 541-546.
27. Giantonio, B. J.; Catalono, P. J.; Meropol, N. J.; O'Dwyer, P. J.; Mitchell, E. P.; Alberts, S. R.; Schwartz, M. A.; Benson, A. B., (III). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. J. Clin. Oncol. 2007, 25, 1539-1544.
28. Johnson, D. H.; Fehrenbacher, L.; Novotny, W. F.; Herbst, R. S.; Nemunaitis, J. J.; Jablons, D. M.; Langer, C. J.; De Vore, R. F. 3rd.; Gaudreault, J.; Damico, L. A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 2004, 22, 2184-2191.
29. Asgari, M. M.; Haggerty, J. G.; McNiff, J. M.; Milstone, L. M.; Schwartz, P. M. Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J. Cutan. Pathol. 1999, 26, 287-294.
30. Sauter, E. R.; Coia, L. R.; Eisenberg, B. L.; Ridge, J. A. Radiation treatment decreases transforming growth factor alpha expression in squamous carcinoma of the tongue. Cancer Lett. 1994, 78, 159-162.
31. Reiss, M.; Munoz-Antonia, T.; Cowan, J. M.; Wilkins, P. C.; Zhou, Z. L.; Vellucci, V. F. Resistance of human squamous carcinoma cells to transforming growth factor beta 1 is a recessive trait. Proc. Natl. Acad. Sci. USA 1993, 90, 6280-6284.
32. Janot, F.; El-Naggar, A. K.; Morrison, R. S.; Liu, T. J.; Taylor, D. L.; Clayman, G. L. Expression of basic fibroblast growth factor in squamous cell carcinoma of the head and neck is associated with degree of histologic differentiation. Int. J. Cancer 1995, 64, 117-123.
33. Cohen, R. F.; Contrino, J.; Spiro, J. D.; Mann, E. A.; Chen, L. L.; Kreutzer, D. L. Interleukin-8 expression by head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 1995, 121, 202-209.
34. Mineta, H.; Miura, R.; Ogino, T.; Takebayashi, S.; Misawa, K.; Ueda, Y.; Suzuki, I.; Dictor, M.; Borg, A.; Wennerberg, J. Prognostic value of vascular endothelial growth factor in patients with head and neck squamous cell carcinomas. Br. J. Cancer 2000, 83, 775-781.
35. Riedel, F.; Gotte, K.; Li, M.; Hormann, K.; Grandis, J. R. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo. Int. J. Oncol. 2003, 23, 577-583.
36. Dray, T. G.; Hardin, N. J.; Sofferman, R. A. Angiogenesis as a prognostic marker in early head and neck cancer. Ann. Otol. Rhinol. Laryngol. 1995, 104, 724-729.
37. Tae, K.; El-Naggar, A.; Yoo, E.; Feng, L.; Lee, J. J.; Hong, W. K.; Hittelman, W. N.; Shin, D. M. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin. Cancer Res. 2000, 6, 2821-2828.
38. Mirabelli, C. K.; Bennett, C. F.; Anderson, K.; Crooke, S. T. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des. 1991, 6, 647-661.
39. Nakashima, T.; Hudson, M.; Clayman, G. L. Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma. Head Neck 2000, 22, 483-488.
40. Neuchrist, C.; Bohan, M.; Erovic, M. D. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003, 25, 464-473.
41. Li, M.; Ye, C.; Feng, C.; Riedel, F.; Liu, X.; Zeng, Q.; Grandis, J. R. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin. Cancer Res. 2002, 8, 3570-3578.
42. Petruzzelli, G. J.; Benefield, J.; Taitz, A. D.; Fowler, S.; Kalkanis, J.; Scobercea, S.; West, D.; Young, M. R. Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferation. Head Neck 1997, 19, 576-582.
43. Pammer, J.; Weninger, W.; Mildner, M.; Burian, M.; Wojta, J.; Tschachler, E. Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy individuals. J. Pathol. 1998, 186, 186-191.
44. Riedel, F.; Gotte, K.; Schwalb, J.; Wirtz, H.; Bergler, W.; Hormann, K. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur. Arch. Otorhinolaryngol. 2000, 257, 332-336.
45. Riedel, F.; Gotte, K.; Schwalb, J.; Schafer, C.; Hormann, K. Vascular endothelial growth factor expression correlates with angiogenesis and p53 mutations in head and neck squamous cell carcinoma. Acta Otolaryngol. 2000, 120, 105-11.
46. Dray, T. G.; Hardin, N. J.; Sofferman, R. A. Angiogenesis as a prognostic marker in early head and neck cancer. Ann. Otol. Rhinol. Laryngol. 1995, 104, 724-729
47. Teknos, T. N.; Cox, C.; Yoo, S.; Chepeha, D. B.; Wolf, G. T.; Bradford, C. R.; Carey, T. E.; Fisher, S. G. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 2002, 24, 1004-1011.
48. Dietz, A.; Rudat, V.; Conradt, C.; Weidauer, H.; Ho, A.; Moehler, T. Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy. Head Neck 2000, 22, 666-673.
49. Tseng, J. E.; Glisson, B. S.; Khuri, F. R.; Shin, D. M.; Myers, J. N.; El-Naggar, A. K.; Roach, J. S.; Ginsberg, L. E.; Thall, P. F.; Wang, X.; Teddy, S.; Lawhorn, K. N.; Zentgraf, R. E.; Steinhaus, G. D.; Pluda, J. M.; Abbruzzese, J. L.; Hong, W. K.; Herbst, R. S. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001, 92, 2364-2373.
50. Vokes, E. E.; Cohen, E. E. W.; Mauer, A. M.; Karrison, T. G.; Wong, S. J.; Skoog-Sluman, L. J.; Kozloff, M. F.; Dancey, J.; Dekker, A. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23(Suppl. 16S), 5504
51. Klos, K. S.; Zhou, X.; Lee, S.; Zhang, L.; Nagata, Y.; Yu, D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2 mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003, 98, 1377-1385.
52. Asakuma, J.; Sumitomo, M.; Asano, T.; Asano, T.; Hayakawa, M. Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. J. Urol. 2004, 171, 897-902.
53. Petit, A. M.; Rak, J.; Hung, M. C.; Rockwell, P.; Goldstein, N.; Fendly, B.; Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and Erb-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 1997, 151, 1523-1530.
54. Viloria-Petit, A.; Crombet, T.; Jothy, S.; Hicklin, D.; Bohlen, P.; Schlaeppi, J. M.; Rak, J. Kerbel, R. S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001, 61, 5090-5101.
55. Dannenberg, A. J.; Lippman, S. M.; Mann, J. R.; Subbaramaiah, K.; DuBois, R. N. Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J. Clin. Oncol. 2005, 23, 254-266.
56. Choe, M. S.; Zhang, X.; Shin, H. J.; Shin, D. M.; Chen, Z. G. Interaction between EGFR and COX-2 mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol. Cancer Ther. 2005, 4, 1448-1455.
57. Ratain, M. J. Advances in drug development. Clin. Adv. Hematol. Oncol. 2005, 3, 371-372.
58. Giatromanolaki, A.; Koukourakis, M. I.; Comley, M.; Kaklamanis, L.; Turley, H.; O'Byrne, K.; Harris, A. L.; Gatter, K. C. Platelet derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J. Pathol. 1997, 181, 196-199.
59. Tannock, I. F.; Hill, R. P. The basic science of oncology; 3rd. ed, McGraw-Hill, 1998.
60. Cenni, E.; Perut, F.; Zuntini, M.; Granchi, D.; Amato, I.; Avnet, S.; Brandi, M. L.; Giunti, A.; Baldini, N. Inhibition of angiogenic activity of renal carcinoma by an antisense oligonucleotide targeting fibroblast growth factor-2. Anticancer Res. 2005, 25, 1109-1113.
61. O'Reilly, M. S.; Boehm, T.; Shing, Y. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell 1994, 79, 315-328.
62. Sugarbaker, E.; Thornwait, J.; Ketcham, A. Inhibitory effect of a primary tumor on metastasis. Day, S.; Myers, P.; Stanley. Progress in cancer research and therapy; Raven Press: New York, NY, 1977, pp. 227-240.
63. Sim, B. K.; O'Reilly, M. S.; Liang, H. A recombinant human angiostatin inhibits experimental primary and metastatic cancer. Cancer Res. 1997, 57, 1329-1334.
64. Mauceri, H. J.; Hanna, N.; Beckett, M. A. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 1998, 394, 287-291.
65. O'Reilly, M. S.; Boehm, T.; Shing, Y. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88, 277-285.
66. Boehm, T.; Folkman, J.; Shing, Y. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390, 404-407.
67. Black, W. R.; Agner, R. C. Tumor regression after endostatin therapy. Nature 1998, 391, 450.
68. Kurup, A.; Lin, C.-W.; Murry, D. J.; Dobrolecki, L.; Estes, D.; Yiannoutsos, C. T.; Mariano, L.; Sidor, C.; Hickey, R.; Hanna, N. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer: A phase II study from Indiana University. Ann. Oncol. 2006, 17, 97-103.
69. Beerepoot, L. V.; Witteveen, E. O.; Groenewegen, G.; Fogler, W. E.; Sim, B. K.; Sidor, C.; Zonnenberg, B. A.; Schramel, F.; Gebbink, M. F.; Voest, E. E. Recombinant human angiostatin by twice daily subcutaneous injection in advanced cancer: a pharmacokinetic and long term safety study. Clin. Cancer Res. 2003, 9, 4025-4033.
70. Farhadi, M. R.; Capelle, H. H.; Erber, R.; Ullrich, A.; Vajkoczy, P. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J. Neurosurg. 2005, 103, 363-370.
71. Karameris, A.; Panagou, P.; Tsilalis, T.; Bouros, D. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous cell lung carcinomas. A molecular and immunohistochemical study. Am. J. Respir. Crit. Care. Med. 1997, 156, 1930-1936.
72. Hidalgo, M.; Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 2001, 93, 178-193.
73. Ozdemir, E.; Kakehi, Y.; Okuno, H. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J. Urol. 1999, 161, 1706-1763.
74. Shou, Y.; Hirano, T.; Gong, Y. Influence of angiogenic factors and matrix metalloproteinases upon tumor progression in non-small cell lung cancer. Br. J. Cancer 2001, 85, 1706-1712.
75. Khokha, R.; Benhardt, D. T. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 1989, 9, 391-405.
76. Douillard, J. Y.; Pexchel, C.; Shepherd, F.; Paz-Ares, L.; Arnold, A.; Davis, M.; Tonato, M.; Smylie, M.; Tu, D.; Voi, M.; Humphrey, J.; Ottaway, J.; Young, K.; Vreckem, A. V.; Seymour, L. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-27591 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2004, 46, 361-368.
77. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
78. Risau, W. Mechanisms of angiogenesis. Nature 1997, 386, 671-674.
79. Vailhe, B.; Vittet, D.; Feige, J. J. In vitro models of vasculogenesis and angiogenesis. Lab. Invest. 2001, 81, 439-452.
80. Bell, S. E.; Mavila, A.; Salazar, R.; Bayless, K. J.; Kanagala, S.; Maxwell, S. A.; Davis, G. E. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J. Cell Sci. 2001, 114, 2755-2773.
81. Gerritsen, M. E.; Soriano, R.; Yang, S.; Ingle, G.; Zlot, C.; Toy, K.; Winer, J.; Draksharapu, A.; Peale, F.; Wu, T. D.; Williams, P. M. In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol. Genomics 2002, 10, 13-20.
82. Grove, A. D.; Prabhu, V. V.; Young, B. L.; Lee, F. C.; Kulpa, V.; Munson, P. J.; Kohn, E. C. Both protein activation and gene expression are involved in early vascular tube formation in vitro. Clin. Cancer Res. 2002, 8, 3019-3026.
83. Hahn, C. N.; Su, Z. J.; Drogemuller, C. J.; Tsykin, A.; Waterman, S. R.; Brautigan, P. J.; Yu, S.; Kremmidiotis, G.; Gardner, A.; Solomon, P. J.; Goodall, G. J.; Vadas, M. A.; Gamble, J. R. Expression profiling reveals functionally important genes and coordinately regulated signaling pathway genes during in vitro angiogenesis. Physiol. Genomics 2005, 22, 57-69.
84. Godl, K.; Gruss, O. J.; Eickoff, J.; Wissing, J.; Blencke, S.; Weber, M.; Degen, H.; Brehmer, D.; Orfi, L.; Horvath, Z.; Keri, G.; Muller, S.; Cotton, M.; Ullrich, A.; Daub, H. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res. 2005, 65, 6919-6926.
85. Shim, J. S.; Kwon, H. J. Chemical genetics for therapeutic target mining. Exp. Opin. Ther. Targets 2004, 8, 653-661.
86. Nanda, A.; St Croix, B. Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol. 2004, 16, 44-49.
87. Halin, C.; Rondini, S.; Nilsson, F.; Berndt, A.; Kosmehl, H.; Zardi, L.; Neri, D. Enhancement of antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 2002, 20, 264-269.